Description Log in to mark as a favorite
Chief Investment Officers Bob Doll, Barry James, and Finny Kuruvilla gather to discuss their perspectives on the markets, as well as their work in constructing and managing portfolios.
About the Speakers
Bob Doll
Crossmark Global InvestmentsBob Doll is Chief Executive Officer and Chief Investment Officer at Crossmark Global Investments and a member of the Kingdom Advisors Board of Directors. He is a highly respected authority on equities markets among investors, advisors, and the media. Through his widely followed weekly and quarterly investment commentaries, as well as annual market predictions, Bob provides ongoing, timely market perspectives. Prior to arriving at Crossmark, he held the roles of Senior Portfolio Manager and Chief Equity Strategist at Nuveen and Blackrock, President and Chief Investment Officer at Merrill Lynch Investment Managers, and Chief Investment Officer at Oppenheimer Funds, Inc.
Barry James
James Investment ResearchBarry James, CFA, CIC Barry is the CEO of James Investment Research and the President of the James Advantage Funds. He received his undergraduate degree from The Unite d States Air Force Academy and his Master’s Degree from Boston University. He joined James Investment Research in its beginning years before a tour of duty as an instructor/fighter pilot with the United States Air Force. He returned to the company in 1986. Barry currently oversees the management of James Investment Research and is a senior member of the firm’s Investment Committee. As company spokesman, he makes frequent national television appearances on CNBC, Market Watch, Fox Business, and Bloomberg TV, as well as being quoted in Barron’s, The Wall Street Journal and numerous other financial publications.
Finny Kuruvilla
EventideFinny Kuruvilla, MD, PhD, serves as a Co-Chief Investment Officer, Senior Portfolio Manager for Eventide’s strategic growth strategies and healthcare & life sciences strategies, a Managing Director for Eventide Ventures, as well as Founding Member of Eventide. Dr. Kuruvilla has a unique background in healthcare, statistics, and investing. Concurrent with his early years at Eventide, he was a Principal at Clarus Ventures, a healthcare and life sciences venture capital firm subsequently acquired by Blackstone. Earlier in his career, Dr. Kuruvilla was a postdoctoral research fellow at the Broad Institute of Harvard and MIT, where he led the development of a new microarray between the Broad Institute and a publicly-traded company Affymetrix. Prior to his investing career, Dr. Kuruvilla was resident, chief resident, and fellow at the Brigham and Women’s Hospital and Boston Children’s Hospital.
Dr. Kuruvilla holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a SM in Electrical Engineering and Computer Science from MIT, and a BS in Chemistry from Caltech.
© 2024 Kingdom Advisors | Privacy Policy | Cookie Policy | Terms of Use
